Literature DB >> 12626537

Forced expression of the Fc receptor gamma-chain renders human T cells hyperresponsive to TCR/CD3 stimulation.

Madhusoodana P Nambiar1, Carolyn U Fisher, Anil Kumar, Christos G Tsokos, Vishal G Warke, George C Tsokos.   

Abstract

High level expression of Fc epsilon RI gamma chain replaces the deficient TCR zeta-chain and contributes to altered TCR/CD3-mediated signaling abnormalities in T cells of patients with systemic lupus erythematosus. Increased responsiveness to Ag has been considered to lead to autoimmunity. To test this concept, we studied early signaling events and IL-2 production in fresh cells transfected with a eukaryotic expression vector encoding the Fc epsilon RI gamma gene. We found that the overexpressed Fc epsilon RI gamma chain colocalizes with the CD3 epsilon chain on the surface membrane of T cells and that cross-linking of the new TCR/CD3 complex leads to a dramatic increase of intracytoplasmic calcium concentration, protein tyrosine phosphorylation, and IL-2 production. We observed that overexpression of Fc epsilon RI gamma is associated with increased phosphorylation of Syk kinase, while the endogenous TCR zeta-chain is down-regulated. We propose that altered composition of the CD3 complex leads to increased T cell responsiveness to TCR/CD3 stimulation and sets the biochemical grounds for the development of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626537     DOI: 10.4049/jimmunol.170.6.2871

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

Authors:  K W Frommer; M Geyer; G S Firestein
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 3.  The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.

Authors:  Wen-Hai Shao; Philip L Cohen
Journal:  Expert Rev Clin Immunol       Date:  2014-03-29       Impact factor: 4.473

Review 4.  Small molecules in the treatment of systemic lupus erythematosus.

Authors:  Anastasia Markopoulou; Vasileios C Kyttaris
Journal:  Clin Immunol       Date:  2012-10-02       Impact factor: 3.969

Review 5.  Novel molecular targets in the treatment of systemic lupus erythematosus.

Authors:  José C Crispín; George C Tsokos
Journal:  Autoimmun Rev       Date:  2007-12-04       Impact factor: 9.754

6.  Proximal signaling control of human effector CD4 T cell function.

Authors:  Francesca I Okoye; Sandeep Krishnan; Meena R Chandok; George C Tsokos; Donna L Farber
Journal:  Clin Immunol       Date:  2007-08-09       Impact factor: 3.969

Review 7.  Systemic lupus erythematosus: new molecular targets.

Authors:  José C Crispín; Vasileios Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 8.  Abnormalities of T cell signaling in systemic lupus erythematosus.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  Arthritis Res Ther       Date:  2011-03-17       Impact factor: 5.156

9.  Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.

Authors:  Alexandros P Grammatikos; Debjani Ghosh; Amy Devlin; Vasileios C Kyttaris; George C Tsokos
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

10.  FcRγ controls the fas-dependent regulatory function of lymphoproliferative double negative T cells.

Authors:  Stephen C Juvet; Christopher W Thomson; Edward Y Kim; Mei Han; Li Zhang
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.